ReviewMolecular therapy : the journal of the American Society of Gene Therapy2017
Nanomaterial-Enabled Cancer Therapy.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.
- Pooled it
- Graphene Quantum Dots in Neurodegeneration: Protein Aggregation and the Microglial State as Therapeutic Targets.Nanomaterials (Basel, Switzerland) · 2026Review
- Machine learning reshapes the paradigm of nanomedicine research.Acta pharmaceutica Sinica. B · 2026Review
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026Review
- Utilizing nanotechnology to diagnose and treat central nervous system disorders.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Challenges and perspectives of CAR-T cell therapy in solid tumours: insights from gastric cancer.British journal of cancer · 2025Review
- Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer.Pharmaceutics · 2025Review
- Green-synthesized metal nanoparticles: a promising approach for accelerated wound healing.Frontiers in bioengineering and biotechnology · 2025Review
- Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems.Frontiers in bioengineering and biotechnology · 2025Review
- Chemical synthesis, characterization, and anticancer potential of CuO/ZrORSC advances · 2024Article
- Mapping the intellectual structure and emerging trends for the application of nanomaterials in gastric cancer: A bibliometric study.World journal of gastrointestinal oncology · 2024Article
- Enhancing drug penetration in solid tumors via nanomedicine: Evaluation models, strategies and perspectives.Bioactive materials · 2024Review
- Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges.International journal of nanomedicine · 2024Review
- Catalytic Nanomedicine as a Therapeutic Approach to Brain Tumors: Main Hypotheses for Mechanisms of Action.Nanomaterials (Basel, Switzerland) · 2023Article
- Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy.Biomaterials research · 2023Article
- Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.RSC advances · 2023Review
- Recent advances in bacterial therapeutics based on sense and response.Acta pharmaceutica Sinica. B · 2023Review
- How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature.International journal of nanomedicine · 2023Review
- Interactions between gold nanoparticles with different morphologies and human serum albumin.Frontiers in chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While cancer remains the major cause of death worldwide, nanomaterial (NM)-based diagnosis and treatment modalities are showing remarkable potential to better tackle clinical oncology by effectively targeting therapeutic agents to tumors. NMs can selectively accumulate in solid tumors, and they can improve the bioavailability and reduce the toxicity of encapsulated cytotoxic agents. Additional noteworthy functions of NMs in cancer treatment include the delivery of contrast agents to image tumor sites, delivery of genetic materials for gene therapy, and co-delivery of multiple agents to achieve combination therapy or simultaneous diagnostic and therapeutic outcomes. Although several NM therapeutics have been successfully translated to clinical applications, the gap between the bench and the bedside remains ominously wide. Tumor heterogeneity and the disparity between pre-clinical and clinical studies have been identified as two of the major translational challenges of NM-based cancer therapies. Herein, we review a handful of recent research studies on the use of NMs in cancer therapy and imaging, with a limited discussion on the consequences of tumor heterogeneity and pre-clinical studies on translational research of NM-based delivery systems and propositions in the literature to overcome these challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.